Factbox: US government to impose inflation penalties on 27 drugs

Bausch Health Companies

15/03/2023 15:18

March 15 (Reuters) - The U.S. government said on
Wednesday it will subject 27 drugs to inflation penalties, a
move that will require the pharmaceutical companies to pay
Medicare rebates if they raise prices at a faster pace than the
rise in inflation rate.
    Under the new provisions, the government will start
invoicing the companies for the rebates in 2025, but Medicare
members will see a reduction in out-of-pocket costs starting
April.
    Here is a list of the drugs and companies:
    
 DRUG NAME   USED FOR             MANUFACTURER      U.S. NET
                                                    SALES IN
                                                    2022 
 Humira      Arthritis            AbbVie Inc        $18.62
                                   ABBV.N           billion 
 Yescarta    Blood cancer         Gilead Sciences   $747
                                  Inc  GILD.O       million
 Padcev      Urothelial cancer    Seagen Inc        $451
                                   SGEN.O           million
 Xiaflex     Peyronie's disease   Endo              $438.7
                                  International     million
                                  Plc  ENDPQ.PK     
 Tecartus    Blood cancer         Gilead Sciences   $221
                                  Inc  GILD.O       million
 Mircera     Anemia               Roche  ROG.S      408 million
                                                    Swiss
                                                    Francs 
                                                    ($442.66
                                                    million) in
                                                    global
                                                    sales 
 Fetroja     Serious bladder or   Shionogi & Co     7.3 billion
             kidney infections    Ltd  4507.T       yen in
             in adults                              Apr-Dec
                                                    2022 ($54.6
                                                    million)
 Fragmin     Treat blood clots    Pfizer Inc        $4 million 
                                   PFE.N            
 Abelcet     Invasive fungal      Leadiant          Data
             infections           Biosciences       unavailable
 Akynzeo     Prevention of        Helsinn           Data
             chemotherapy-induce  Healthcare S.A    unavailable
             d nausea and                           
             vomiting                               
 Atgam       Used after kidney    Pfizer Inc        Data
             transplant to keep    PFE.N            unavailable
             the body from                          
             rejecting the organ                    
 Aveed       Treat low            Endo              Data
             testosterone in      International     unavailable
             adult males          Plc  ENDPQ.PK     
 Bicillin    Antibiotic           Pfizer Inc        Data
 C-R                               PFE.N            unavailable
 Bicillin    Antibiotic           Pfizer Inc        Data
 L-A                               PFE.N            unavailable
 Carnitor    Carnitine            Leadiant          Data
             deficiency           Biosciences       unavailable
 Cytogam     To prevent a         Kamada Ltd        Data
             cytomegalovirus       KMDA.TA          unavailable
             disease infection                      
             in transplant                          
             patients                               
 Elzonris    Rare form of blood   Menarini Group    Data
             cancer                                 unavailable
 Flebogamma  Treatment for        Grifols SA        Data
 DIF         primary               GRLS.MC          unavailable
             immunodeficiency                       
             and autoimmune                         
             disease                                
 Folotyn     T-cell lymphoma      Acrotech          Data
                                  Biopharma LLC     unavailable
 Leukine     Blood cancer         Partner           Data
                                  Therapeutics      unavailable
 Minocin     To prevent           Bausch Health     Data
             infections in        Companies         unavailable
             hospitalized          BHC.TO           
             patients                               
 Nipent      Blood cancer         Pfizer Inc        Data
                                   PFE.N            unavailable
 Rybrevant   Lung cancer          Johnson &         Data
                                  Johnson  JNJ.N    unavailable
 Signifor    For the rare         Recordati         Data
 LAR         diseases Acromegaly                    unavailable
             and Cushing's                          
             disease                                
 Sylvant     Multicentric         EUSA Pharma (US)  Data
             Castleman's disease  LLC               unavailable
 Winrho SDF  Bleeding disorder    Kamada Ltd's      Data
                                   KMDA.TA          unavailable
 Xipere      Eye disease macular  Bausch and        Data
             edema associated     Lomb's  BLCO.TO   unavailable
             with uveitis                           
 
($1 = 0.9217 Swiss francs)

 (Compiled by Aditya Samal and Leroy leo; Editing by Shinjini
Ganguli)
 ((Aditya.Samal@thomsonreuters.com;))